Morphic announces corporate highlights and financial results for the second quarter 2023

-reported positive topline results from emerald-1 study of morf-057 in ulcerative colitis- -continued enrollment on target in emerald-2 phase 2b trial of morf-057 in ulcerative colitis- -greater than $730 million in cash and equivalents at 6/30/23; extended cash runway into second half of 2027- -new clinical trials of morf-057 in crohn's disease and morf-088 in myelofibrosis to begin in the first half of 2024- waltham, mass., aug. 03, 2023 (globe newswire) -- morphic therapeutic (nasdaq: morf), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the second quarter of 2023.
MORF Ratings Summary
MORF Quant Ranking